APLM - Apollomics Inc. Class A Ordinary Shares

APLM - Apollomics Inc. Class A Ordinary Shares

https://www.apollomicsinc.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib - Apollomics ( NASDAQ:APLM ) , Apollomics ( NASDAQ:APLMW )

Benzinga • 5 months, 2 weeks ago • score: 0.16

LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia ( excluding mainland China, Hong Kong and Macau ) for the treatment of non-small cell lung cancer ( "NSCLC" )

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Business Insider • 5 months, 2 weeks ago • score: 0.26

Apollomics and LaunXP Announce Development and Commercialization Agreement for ...

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

GlobeNewswire • 5 months, 2 weeks ago • score: 0.16

FOSTER CITY, Calif. and TAIPEI, Taiwan, March 31, 2025 ( GLOBE NEWSWIRE ) -- Apollomics Inc. ( Nasdaq: APLM ) ( "Apollomics" ) , a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, and LaunXP ...

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

GlobeNewswire • 8 months, 3 weeks ago • score: 0.08

FOSTER CITY, Calif., Dec. 20, 2024 ( GLOBE NEWSWIRE ) -- Apollomics Inc. ( Nasdaq: APLM ) ( "Apollomics" or the "Company" ) , a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced ...

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement - Apollomics ( NASDAQ:APLM ) , Apollomics ( NASDAQ:APLMW )

Benzinga • 9 months ago • score: 0.10

FOSTER CITY, Calif., Dec. 10, 2024 ( GLOBE NEWSWIRE ) -- Apollomics Inc.

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

GlobeNewswire • 9 months ago • score: 0.10

FOSTER CITY, Calif., Dec. 10, 2024 ( GLOBE NEWSWIRE ) -- Apollomics Inc. ( Nasdaq: APLM ) ( the "Company" ) , a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that on December 10, 2024, it received a notification ( the ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company is headquartered in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.

52W High

$19.40

52W Low

$3.66

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.89

Valuation

As of 2024-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.10

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

28.75

P/B (<3 favorable)

1.17

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

36.50%

Institutions (25–75% balanced)

0.67%

Shares Outstanding

1,103,400

Float

774,630

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2024-06-30 (Overview)

Revenue (TTM)

198,000

Gross Profit (TTM)

198,000

EPS (TTM)

-52.80

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

10.07%

ROE (TTM) (>15% strong)

-2.34%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

2.62

Momentum

Bearish momentum

Value

0.1379

Previous

0.0033

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025